New therapies for the treatment of multiple myeloma.
Richardson
Paul
P
Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D001897:Boronic Acids; D010975:Platelet Aggregation Inhibitors; D011089:Polydeoxyribonucleotides; D011480:Protease Inhibitors; D011719:Pyrazines; C036901:defibrotide; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide